Period:
Draw Mode:
| Volume | 0.00 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Cell Source Inc (PK) | CLCS | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 0.45 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.45 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0.00 | - | 0.0024 - 1.50 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.45 | USD |
Cell Source Inc (PK) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 16.74M | 37.19M | 6.85M | $ - | $ - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 153.00 | $ - | - | - | - |
Cell Source (PK) News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CLCS Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.42 | 0.49 | 0.42 | 0.4860559 | 6,488 | 0.03 | 7.14% |
| 1 Month | 0.29 | 0.56 | 0.28 | 0.3908443 | 9,439 | 0.16 | 55.17% |
| 3 Months | 0.67 | 1.00 | 0.26 | 0.3811946 | 14,931 | -0.22 | -32.84% |
| 6 Months | 0.0024 | 1.50 | 0.0024 | 0.4110247 | 13,427 | 0.4476 | 18,650.0% |
| 1 Year | 0.749 | 1.50 | 0.0024 | 0.4622626 | 9,713 | -0.299 | -39.92% |
| 3 Years | 0.55 | 2.55 | 0.0024 | 1.09 | 7,154 | -0.10 | -18.18% |
| 5 Years | 0.425 | 2.55 | 0.0024 | 0.9780375 | 6,299 | 0.025 | 5.88% |
Cell Source (PK) Description
| We are engaged in the development and commercialization of the patented technology which we license. We are currently sponsoring a clinical trial in the US. Our principal operations are focused on developing innovative cell therapy products focused on the treatment of blood cancers and nonmalignant blood disorders as well as the facilitation of safer and more accessible organ transplantations. |